Want to impress Novartis' CEO? Don't do it in PowerPoint

Novartis ($NVS) CEO Joe Jimenez (photo) tells the New York Times a few things: He's more patient than he used to be. He's learned how to open the door to bad news. And he's not one to compliment a 75-page PowerPoint presentation. Report

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.